Pull to refresh
Logo
FDA approves first drug for the brain symptoms of Type 3 Gaucher disease

FDA approves first drug for the brain symptoms of Type 3 Gaucher disease

New Capabilities

Sanofi's Infilbray is an oral pill that crosses the blood-brain barrier, arriving as the company braces for Dupixent's patent expiration

Overview

Updated 44 minutes ago

For people with Type 3 Gaucher disease, enzyme infusions have kept the body working while the brain kept slipping. The Food and Drug Administration has now approved Infilbray, the first drug cleared to treat the disease's neurological symptoms.

Sanofi inherited the pill from its 2011 purchase of Genzyme and tested it against Parkinson's disease, a kidney disorder and two other lysosomal storage diseases before it worked here. The approval adds a rare disease revenue line as Dupixent, the company's top-selling drug, approaches patent expiration.

Why it matters

Type 3 Gaucher patients get the first drug that reaches the brain, and Sanofi gets a small hedge against Dupixent's patent cliff.

Questions about this story

Free account needed to ask — your question is kept and asked for you right after sign-up. Answers are public.

No questions yet — be the first to ask.

Key Indicators

1st
First approved drug for GD3 neurological symptoms
No previous therapy treated the brain and nerve damage caused by Type 3 Gaucher disease.
43
Patients in the LEAP2MONO trial
Randomized one-to-one to venglustat or imiglucerase infusions for 52 weeks.
0.0137
p-value on the primary endpoint
The trial's combined ataxia and cognition measure favored venglustat over enzyme infusions.
15 kg
Minimum patient weight for approval
About 33 pounds; the label covers adults and children above that threshold.
10%
Depression rate among trial patients on venglustat
No patients on imiglucerase reported depression; suicidal ideation is a labeled warning.

Voices

Curated perspectives — historical figures and your fellow readers.

Sign up to generate historical perspectives on this story.

People Involved

Organizations Involved

Timeline

2011 November 2026

3 events Latest: 3 days ago
  1. FDA clears Infilbray for Type 3 Gaucher brain symptoms

    Latest Approval

    The oral pill is the first cleared for the disease's neurological manifestations; Sanofi has not disclosed pricing.

  2. Cerezyme's label expands to Type 3 body symptoms

    Regulatory

    The enzyme therapy's US label adds non-neurological Type 3 Gaucher symptoms, nearly 30 years after Europe.

  3. Sanofi buys Genzyme

    Deal

    Sanofi acquires the rare disease drugmaker, taking on the experimental compound that became Infilbray.

Scenarios

1

European regulators clear Infilbray, extending the label beyond the US

Likely Resolves by End of 2027

Discussed by: Sanofi, whose approval announcement says the drug is under review in the EU, Japan and other markets

Sanofi said the drug is under regulatory review in Europe and Japan and that it will file in more countries through 2026 and 2027. A positive opinion from the European Medicines Agency would be followed by a European Commission decision, which is the step that actually authorizes sale.

2

Infilbray sales stay small next to Dupixent's decline

Likely Resolves by Feb 28, 2028

Discussed by: RBC Markets analyst Trung Huynh, who wrote in September that sales expectations are modest

A label limited to one form of a rare disease caps how many patients can take the drug, and the price is undisclosed. Huynh's note argues Sanofi needs several rare disease successes, not one, to offset the revenue it loses as Dupixent patents expire.

3

Post-marketing reports push the FDA to a stricter psychiatric warning

Possible Resolves by Nov 30, 2028

Discussed by: The FDA label, which already warns of suicidal thoughts and behavior, and trial data showing depression in 10% of venglustat patients versus none on imiglucerase

The drug reached market with a warning, not a boxed warning, the FDA's most serious safety alert. If reports after launch show suicidal ideation or behavior at higher rates than the trial suggested, the agency can escalate the label or add a restricted-distribution program.

Historical Context

3 moments from history that rhyme with this story — and how they unfolded.

2011

Sanofi buys Genzyme (2011)

Sanofi acquired Genzyme, the rare disease drugmaker whose enzyme therapies had turned Gaucher disease from a fatal diagnosis into a manageable one. The deal brought Sanofi a pipeline of experimental compounds, including a glucosylceramide synthase inhibitor that had not yet been tested in patients.

Then

Sanofi gained a rare disease business and a set of unproven molecules it spent years evaluating against different disorders.

Now

The compound failed in Parkinson's disease, a rare kidney condition, GM2 gangliosidosis and Fabry disease before succeeding in Type 3 Gaucher.

Why this matters now

The drug approved this month is a 15-year-old inheritance, not a fresh discovery.

2026

Cerezyme's Type 3 label expansion (2026)

Earlier in 2026, the FDA expanded Cerezyme (imiglucerase) to cover the non-neurological symptoms of Type 3 Gaucher disease in adults. The decision came nearly 30 years after the same indication was approved in Europe.

Then

The label covered the body symptoms of Type 3 Gaucher, which enzyme infusions can treat.

Now

The brain and nerve damage was still outside the drug's reach.

Why this matters now

It shows how long the neurological half of this disease went without an approved treatment.

2014

Eliglustat, the first oral Gaucher drug (2014)

Genzyme's eliglustat (Cerdelga) showed that blocking glucosylceramide synthase, the enzyme that produces the fatty substances that build up in Gaucher, could control the disease with a pill instead of infusions. The drug does not cross the blood-brain barrier.

Then

Patients with Type 1 Gaucher gained an oral alternative to biweekly infusions.

Now

The mechanism was proven, but the neurological form of the disease remained untreated.

Why this matters now

Venglustat is the same mechanism rebuilt to get past the barrier that kept eliglustat out of the brain.

Sources

(7)